Subclinical thyroid dysfunction and cardiovascular diseases: 2016 update.

Floriani, Carmen; Gencer, Baris; Collet, Tinh-Hai; Rodondi, Nicolas (2018). Subclinical thyroid dysfunction and cardiovascular diseases: 2016 update. European Heart Journal, 39(7), pp. 503-507. Oxford University Press 10.1093/eurheartj/ehx050

[img] Text
Floriani EurHeartJ 2018.pdf - Published Version
Restricted to registered users only until 18 February 2020.
Available under License Publisher holds Copyright.

Download (857kB) | Request a copy

Subclinical thyroid dysfunction comprises subclinical hypothyroidism (SHypo), defined as elevated thyroid-stimulating hormone (TSH) by normal free thyroxine (FT4), and subclinical hyperthyroidism (SHyper) with decreased or undetectable TSH and normal FT4. Up to 10% of the elderly have SHypo, which is usually asymptomatic. Individual participant data (IPD) analyses of prospective cohort studies from the international Thyroid Studies Collaboration show that SHypo is associated with increased coronary heart disease (CHD) mortality [hazard ratio (HR) 1,58 for TSH ≥ 10 mIU/L, 95% CI 1.10-2.27), as well as increased risk of stroke, and heart failure (HF) for both higher and lower TSH. Small studies found that SHypo affects carotid intima media thickness (CIMT), diastolic function, peripheral vascular resistance, endothelial function, and lipid profile. SHyper is associated with increased risk of atrial fibrillation (AF) (HR 1.68, 95% CI 1.16-2.43) and CHD events (HR 1.21, 95% CI 0.99-1.46). The TSH threshold for initiating treatment is unclear. In the absence of large randomized controlled trials, the best evidence suggests SHypo therapy should be started at TSH ≥ 10 mIU/L, and SHyper therapy at TSH < 0.1 mIU/L. Recommendations on screening are discordant, but most guidelines advocate that thyroid function should be checked in those at risk for hypothyroidism, those over 60, and those with known CHD and HF. This review updates current evidence on the association between thyroid dysfunction and cardiovascular disease, as well as on screening and treatment of subclinical thyroid dysfunction.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of General Internal Medicine (DAIM) > Clinic of General Internal Medicine > Centre of Competence for General Internal Medicine
04 Faculty of Medicine > Medical Education > Institute of General Practice and Primary Care (BIHAM)
04 Faculty of Medicine > Department of General Internal Medicine (DAIM) > Clinic of General Internal Medicine

UniBE Contributor:

Floriani, Carmen and Rodondi, Nicolas

Subjects:

600 Technology > 610 Medicine & health
300 Social sciences, sociology & anthropology > 360 Social problems & social services

ISSN:

0195-668X

Publisher:

Oxford University Press

Language:

English

Submitter:

Doris Kopp Heim

Date Deposited:

25 Apr 2017 14:56

Last Modified:

27 Oct 2019 12:00

Publisher DOI:

10.1093/eurheartj/ehx050

PubMed ID:

28329380

Uncontrolled Keywords:

Cardiovascular diseases Screening Subclinical hyperthyroidism Subclinical hypothyroidism TSH Treatment

BORIS DOI:

10.7892/boris.99499

URI:

https://boris.unibe.ch/id/eprint/99499

Actions (login required)

Edit item Edit item
Provide Feedback